#1 Clinical Trials Search in Europe

Ruxotemitide

This article discusses the ongoing clinical trial of Ruxotemitide (also known as LTX-315) in combination with pembrolizumab for patients with advanced melanoma. The study, called NeoLIPA, aims to evaluate the effectiveness and safety of this treatment approach in patients with resectable stage III-IV melanoma before surgery. We’ll explore the trial’s objectives, eligibility criteria, and potential outcomes for patients with this serious skin cancer.

Table of Contents

What is RUXOTEMITIDE?

RUXOTEMITIDE, also known by its sponsor product code LTX-315, is an investigational drug being studied for the treatment of advanced melanoma[1]. It is a protein-based medication that is administered as an injection[1]. This drug is currently being tested in clinical trials to evaluate its effectiveness and safety in treating patients with advanced stages of melanoma.

Medical Conditions Treated

RUXOTEMITIDE is being studied specifically for patients with clinically detectable and resectable stage III-IV melanoma[1]. Melanoma is a type of skin cancer that can be very serious if it spreads to other parts of the body. The stages mentioned in the study refer to:

  • Stage III melanoma: Cancer has spread to nearby lymph nodes but not to distant parts of the body.
  • Stage IV melanoma: Cancer has spread to distant parts of the body, such as the lungs, liver, or brain.

The term “resectable” means that the cancer can be surgically removed, which is an important factor in the treatment plan[1].

How RUXOTEMITIDE is Administered

RUXOTEMITIDE is administered through intratumoral use, which means it is injected directly into the tumor[1]. This method of administration allows the drug to target the cancer cells more directly. The maximum daily dose amount is 40 mg/g, with a maximum total dose amount of 200 mg over a treatment period of up to 5 days[1].

Clinical Trial Details

The clinical trial for RUXOTEMITIDE, known as NeoLIPA, is a phase II open-label study that combines RUXOTEMITIDE (LTX-315) with another drug called pembrolizumab[1]. This combination is being tested as a neoadjuvant treatment, which means it’s given before the main treatment (in this case, surgery) to potentially improve outcomes.

The main goal of the study is to measure the tumor response to this neoadjuvant treatment, specifically looking at the rate of pathological complete response (pCR)[1]. This means the researchers want to see if the treatment can eliminate all detectable cancer cells before surgery.

Eligibility Criteria

To participate in this clinical trial, patients must meet certain criteria. Some key eligibility factors include:

  • Being 18 years of age or older
  • Having confirmed stage III-IV melanoma that can be surgically removed
  • Having at least one tumor that can be injected with the study drug
  • Being in generally good health and able to perform daily activities

There are also factors that would exclude someone from participating, such as having certain other medical conditions or having received specific previous treatments[1].

Potential Benefits

While the effectiveness of RUXOTEMITIDE is still being studied, the researchers hope to see several potential benefits, including:

  • Reduction in tumor size before surgery
  • Improved success of surgery
  • Longer time without the cancer returning after treatment
  • Better overall survival rates

It’s important to note that these are potential benefits, and the actual results of the study are not yet known[1].

Safety Considerations

As with any medical treatment, safety is a crucial consideration. The clinical trial is designed to carefully monitor for any side effects or adverse events related to the treatment. Patients in the study will be closely watched for any reactions to RUXOTEMITIDE or the combination treatment with pembrolizumab[1].

It’s important for patients to discuss all potential risks and benefits with their healthcare provider before considering participation in a clinical trial.

Aspect Details
Study Name NeoLIPA
Study Type Phase II, open-label, single-arm
Main Drug Ruxotemitide (LTX-315)
Combination Drug Pembrolizumab
Target Condition Resectable stage III-IV melanoma
Primary Endpoint Rate of pathologic complete response (pCR)
Key Eligibility Adults with confirmed, resectable stage III-IV melanoma
Treatment Approach Neoadjuvant (before surgery)
Ruxotemitide Administration Intratumoral injection
Max Treatment Period 5 days

FAQ

  • What is Ruxotemitide (LTX-315) and how is it being used in this clinical trial? Ruxotemitide, also known as LTX-315, is an investigational drug being studied in combination with pembrolizumab for the treatment of advanced melanoma. In this trial, it is administered through intratumoral injection, meaning it's injected directly into the tumor, before surgery in patients with resectable stage III-IV melanoma.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults (18 years or older) with confirmed, clinically detectable stage III-IV(M1a) melanoma that can be surgically removed. They must have measurable disease, be medically fit for surgery, and have adequate organ function. Patients with uveal melanoma, brain metastases, or those who have received prior immunotherapy are not eligible.
  • What is the main goal of this clinical trial? The main objective of this trial is to evaluate the tumor response to the neoadjuvant treatment (treatment given before surgery) with Ruxotemitide and pembrolizumab. This is measured by the rate of pathological complete response (pCR), which means no cancer cells are found in the tissue removed during surgery.
  • How long does the treatment last in this trial? The exact duration of treatment is not specified in the provided information. However, the trial involves a neoadjuvant treatment period (before surgery) with Ruxotemitide and pembrolizumab, followed by surgery. The maximum treatment period for Ruxotemitide is mentioned as 5 days, with a maximum total dose of 200 mg.
  • What are the potential benefits and risks of participating in this trial? Potential benefits include access to a new combination therapy that may be effective against advanced melanoma. The trial also closely monitors patients' responses and safety. Risks may include side effects from the medications, which will be carefully monitored. It's important to note that the trial is designed to evaluate both the effectiveness and safety of this treatment approach.

Ongoing Clinical Trials on Ruxotemitide

  • Study of LTX-315 and Pembrolizumab for Patients with Resectable Stage III-IV Melanoma

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Norway

Glossary

  • Melanoma: A type of skin cancer that develops in the cells (melanocytes) that produce melanin, the pigment that gives your skin its color.
  • Neoadjuvant treatment: Treatment given before the main treatment, usually before surgery, to shrink a tumor or kill cancer cells.
  • Ruxotemitide (LTX-315): An investigational drug being studied for the treatment of advanced melanoma, administered through intratumoral injection.
  • Pembrolizumab: An immunotherapy drug that helps the immune system fight cancer cells.
  • Pathological complete response (pCR): When no cancer cells are found in tissue removed during surgery after neoadjuvant treatment.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a set of rules used to measure how well a cancer patient responds to treatment.
  • Intratumoral injection: A method of administering medication directly into a tumor.
  • Resectable: Able to be removed surgically.
  • Neoadjuvant: Treatment given before the main treatment, usually surgery.
  • ECOG performance status: A scale used to assess how a patient's disease is progressing and how it affects daily living abilities.

References

  1. http://clinicaltrials.eu/trial/study-of-ltx-315-and-pembrolizumab-for-patients-with-resectable-stage-iii-iv-melanoma/